Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Huai-Ling Hsu"'
Autor:
Emma J. Buckels, Joey Tan, Huai‐Ling Hsu, Yuting Zhu, Christina M. Buchanan, Brya G. Matthews, Kate L. Lee
Publikováno v:
JBMR Plus, Vol 7, Iss 8, Pp n/a-n/a (2023)
ABSTRACT Preptin is derived from the cleavage of the E‐peptide of pro‐insulin‐like growth factor (IGF)‐II and is an insulin secretagogue. Observational studies have linked elevated circulating preptin to metabolic dysfunction in humans; howev
Externí odkaz:
https://doaj.org/article/881df186734f4c5883a47775a23c16b9
Autor:
Jingli Wang, William R. Wilson, Susan M. Pullen, Jiechuang Su, Huai-Ling Hsu, Francis W. Hunter
Supplementary Figures. Supplementary Figures including correlations of HAP sensitivity between cell lines, development and characterisation of doxycycline-inducible shRNA cell lines, and effect of BRCA2 knockout on radiation sensitivity of DLD-1 tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5024b37df1574f0ecb36039cae084bf4
https://doi.org/10.1158/1535-7163.22502809
https://doi.org/10.1158/1535-7163.22502809
Autor:
Jingli Wang, William R. Wilson, Susan M. Pullen, Jiechuang Su, Huai-Ling Hsu, Francis W. Hunter
Supplementary Tables. Supplementary Tables (including statistical analysis of relationships between one-electron reductase activity, HR status and chemosensitivity) and supplementary references related to this material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38b74e544cf3021c52e6a78e33361d5e
https://doi.org/10.1158/1535-7163.22502806.v1
https://doi.org/10.1158/1535-7163.22502806.v1
Autor:
Michael P. Hay, William R. Wilson, Huai-Ling Hsu, Jingli Wang, Rita Patel, Anthony J. R. Hickey, Francis W. Hunter
Publikováno v:
Biochemical Pharmacology. 83:574-585
CEN-209 (SN30000) is a second-generation benzotriazine di-N-oxide currently in advanced preclinical development as a hypoxia-activated prodrug (HAP). Herein we describe the DNA repair-, hypoxia- and one-electron reductase-dependence of CEN-209 cytoto
Autor:
Jiechuang Su, Jingli Wang, William R. Wilson, Huai-Ling Hsu, Francis W. Hunter, Susan M. Pullen
Publikováno v:
Molecular cancer therapeutics. 13(11)
Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcome and few validated drug targets. Two prevalent features of TNBC, tumor hypoxia and derangement of homologous recombination (HR) repair, are potentially exploit
Publikováno v:
Human Genomics
Human Genomics, Vol 3, Iss 1, Pp 17-23 (2008)
Human Genomics, Vol 3, Iss 1, Pp 17-23 (2008)
There is considerable inter-ethnic variability in the incidence of CYP2C19 genetic poor metabolisers (var/var). About 3 per cent of Caucasians are CYP2C19 var/var. By contrast, an extremely high incidence (70 per cent) is observed in the Melanesian i
Autor:
Huai-Ling Hsu, Amir Ashoorzadeh, Angus C. Grey, Matthew Bull, Jeff B. Smaill, Shevan Silva, Jessica Sun, Adam V. Patterson, Maria R. Abbattista, Charles P. Hart, Robert F. Anderson, Christopher P. Guise
Publikováno v:
Cancer Research. 75:5358-5358
Clinical data indicate that mutant EGFR NSCLC is often heterozygous (PLoS ONE 2013; 8: e54170; PLoS ONE 2009; 4: e7464) and the presence of wild type (WT) EGFR allele is associated with limited response to EGFR-tyrosine kinase inhibitor (TKI) therapy
Autor:
William R. Wilson, Adam V. Patterson, Huai-Ling Hsu, Daniel G. Hurley, Jingli Wang, Christopher P. Guise
Publikováno v:
Cancer Research. 73:2111-2111
Background: SN30000 is a 2nd generation benzotriazine-N-oxide hypoxia-activated prodrug (tirapazamine analogue) and is currently in preclinical development. We have previously shown that reductive activation of the hypoxia marker EF5 and SN30000 are
Autor:
Ho H. Lee, William A. Denny, Aaron Thompson, Maria R. Abbattista, Wouter van Leeuwen, Robert F. Anderson, Amir Ashoorzadeh, Sunali Mehta, Stephen M. F. Jamieson, Alison Pruijn, Fernando Donate, Michelle Puryer, Andrej Maroz, Sophie P. Syddall, Jeff B. Smaill, Huai-Ling Hsu, Jagdish K. Jaiswal, Guo-Liang Lu, William R. Wilson, Adam V. Patterson
Publikováno v:
Molecular Cancer Therapeutics. 10:A247-A247
Hypoxia occurs in most human tumors and is associated with disease progression, treatment resistance and poor patient outcome. We have developed the hypoxia-activated prodrug SN29966, designed to release the irreversible pan-HER inhibitor SN29926, fo